
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1391011/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hydrogen sulfide (H2S) - the third gas of interest for pharmacologists. Pharmacological Reports, 2007, 59, 4-24.	3.3	438
2	Leptin and atherosclerosis. Atherosclerosis, 2006, 189, 47-60.	0.8	421
3	Adverse Effects of Statins - Mechanisms and Consequences. Current Drug Safety, 2009, 4, 209-228.	0.6	179
4	Role of leptin in blood pressure regulation and arterial hypertension. Journal of Hypertension, 2006, 24, 789-801.	0.5	178
5	Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis, 2003, 170, 21-29.	0.8	147
6	Hydrogen sulfide in pharmacology and medicine – An update. Pharmacological Reports, 2015, 67, 647-658.	3.3	124
7	Liver X Receptors (LXR) as Therapeutic Targets in Dyslipidemia. Cardiovascular Therapeutics, 2008, 26, 297-316.	2.5	111
8	Leptin and the regulation of endothelial function in physiological and pathological conditions. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 168-178.	1.9	95
9	Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sciences, 2004, 74, 2987-3000.	4.3	94
10	Adrenomedullinwhat do we know 10 years since its discovery?. Polish Journal of Pharmacology, 2004, 56, 5-27.	0.3	94
11	Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Higieny I Medycyny Doswiadczalnej, 2007, 61, 736-59.	0.1	94
12	Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacological Reports, 2006, 58, 159-78.	3.3	89
13	Differential effects of statins on endogenous H2S formation in perivascular adipose tissue. Pharmacological Research, 2011, 63, 68-76.	7.1	85
14	Hydrogen Sulfide and Endothelium-Dependent Vasorelaxation. Molecules, 2014, 19, 21183-21199.	3.8	78
15	Hypoxia in the Renal Medulla: Implications for Hydrogen Sulfide Signaling. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 358-363.	2.5	75
16	Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. Medical Science Monitor, 2006, 12, RA112-9.	1.1	68
17	Hydrogen sulfide in the regulation of insulin secretion and insulin sensitivity: Implications for the pathogenesis and treatment of diabetes mellitus. Biochemical Pharmacology, 2018, 149, 60-76.	4.4	67
18	Adiponectin and its Role in Cardiovascular Diseases. Cardiovascular & Hematological Disorders Drug Targets, 2008, 8, 7-46.	0.7	66

#	Article	IF	CITATIONS
19	Metabolic Effects of Metformin in the Failing Heart. International Journal of Molecular Sciences, 2018, 19, 2869.	4.1	61
20	Human Leptin Stimulates Systemic Nitric Oxide Production in the Rat. Obesity, 2002, 10, 939-946.	4.0	53
21	Thiazolidinedione-Induced Fluid Retention: Recent Insights into the Molecular Mechanisms. PPAR Research, 2013, 2013, 1-8.	2.4	50
22	Leptin-Induced Endothelium-Dependent Vasorelaxation of Peripheral Arteries in Lean and Obese Rats: Role of Nitric Oxide and Hydrogen Sulfide. PLoS ONE, 2014, 9, e86744.	2.5	50
23	Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis, 2002, 164, 283-288.	0.8	49
24	Synthesis, Metabolism, and Signaling Mechanisms of Hydrogen Sulfide: An Overview. Methods in Molecular Biology, 2019, 2007, 1-8.	0.9	47
25	Paraoxonase 1 activity in different types of multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 399-402.	3.0	45
26	Endogenous hydrogen sulfide in perivascular adipose tissue: role in the regulation of vascular tone in physiology and pathology. Canadian Journal of Physiology and Pharmacology, 2013, 91, 889-898.	1.4	44
27	Statins and Modulation of Oxidative Stress. Toxicology Mechanisms and Methods, 2005, 15, 61-92.	2.7	39
28	Differential effect of antioxidant treatment on plasma and tissue paraoxonase activity in hyperleptinemic rats. Pharmacological Research, 2005, 51, 523-532.	7.1	37
29	Hydrogen Sulfide in the Adipose Tissue—Physiology, Pathology and a Target for Pharmacotherapy. Molecules, 2017, 22, 63.	3.8	35
30	Human leptin administered intraperitoneally stimulates natriuresis and decreases renal medullary Na+, K+-ATPase activity in the rat impaired effect in dietary-induced obesity. Medical Science Monitor, 2002, 8, BR221-9.	1.1	35
31	Liver X receptor (LXR) and the reproductive system – a potential novel target for therapeutic intervention. Pharmacological Reports, 2010, 62, 15-27.	3.3	32
32	Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research. Medical Science Monitor, 2002, 8, RA39-52.	1.1	32
33	Effect of 3-hydroxy-3-methylglutarylcoenzyme A Reductase Inhibitors (Statins) on Tissue Paraoxonase 1 and Plasma Platelet Activating Factor Acetylhydrolase Activities. Journal of Cardiovascular Pharmacology, 2004, 43, 121-127.	1.9	31
34	Regulation of Renal Ouabain-Resistant Na+-ATPase by Leptin, Nitric Oxide, Reactive Oxygen Species, and Cyclic Nucleotides: Implications for Obesity-Associated Hypertension. Clinical and Experimental Hypertension, 2007, 29, 189-207.	1.3	31
35	Protein homocysteinylation: a new mechanism of atherogenesis?. Postepy Higieny I Medycyny Doswiadczalnej, 2005, 59, 392-404.	0.1	31
36	Influence of intravenously administered leptin on nitric oxide production, renal hemodynamics and renal function in the rat. Regulatory Peptides, 2004, 120, 59-67.	1.9	30

#	Article	IF	CITATIONS
37	Role of nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) in the regulation of blood pressure by leptin in lean and obese rats. Life Sciences, 2006, 79, 63-71.	4.3	28
38	Progranulin, a New Adipokine at the Crossroads of Metabolic Syndrome, Diabetes, Dyslipidemia and Hypertension. Current Pharmaceutical Design, 2017, 23, 1533-1539.	1.9	28
39	Modulation of H ₂ S Metabolism by Statins: A New Aspect of Cardiovascular Pharmacology. Antioxidants and Redox Signaling, 2012, 17, 81-94.	5.4	27
40	H2O2 and Src-dependent transactivation of the EGF receptor mediates the stimulatory effect of leptin on renal ERK and Na+, K+-ATPase. Peptides, 2006, 27, 3234-3244.	2.4	26
41	Resistance to acute NO-mimetic and EDHF-mimetic effects of leptin in the metabolic syndrome. Life Sciences, 2009, 85, 557-567.	4.3	26
42	Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: Role in leptin-induced hypertension. Biochemical Pharmacology, 2008, 75, 1623-1638.	4.4	24
43	Triactome: Neuroââ,¬â€œImmuneââ,¬â€œAdipose Interactions. Implication in Vascular Biology. Frontiers in Immunology, 2014, 5, 130.	4.8	24
44	Leptin and the Regulation of Renal Sodium Handling and Renal Na+- Transporting ATPases: Role in the Pathogenesis of Arterial Hypertension. Current Cardiology Reviews, 2010, 6, 31-40.	1.5	23
45	Modulation of paraoxonase 1 and protein N-homocysteinylation by leptin and the synthetic liver X receptor agonist T0901317 in the rat. Journal of Endocrinology, 2010, 204, 191-198.	2.6	22
46	Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy Higieny I Medycyny Doswiadczalnej, 2007, 61, 760-85.	0.1	21
47	Antioxidant treatment normalizes nitric oxide production, renal sodium handling and blood pressure in experimental hyperleptinemia. Life Sciences, 2005, 77, 1855-1868.	4.3	19
48	Renal antioxidant enzymes and glutathione redox status in leptin-induced hypertension. Molecular and Cellular Biochemistry, 2008, 319, 163-174.	3.1	19
49	Role of extracellular signal-regulated kinases (ERK) in leptin-induced hypertension. Life Sciences, 2008, 82, 402-412.	4.3	19
50	Chronic hyperleptinemia induces resistance to acute natriuretic and NO-mimetic effects of leptin. Peptides, 2010, 31, 155-163.	2.4	19
51	Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: Role of vitamin D metabolites. Atherosclerosis, 2011, 219, 526-531.	0.8	19
52	Bidirectional regulation of renal cortical Na+,K+-ATPase by protein kinase C Acta Biochimica Polonica, 2004, 51, 757-772.	0.5	19
53	Hydrogen Sulfide and its Modulation in Arterial Hypertension and Atherosclerosis. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2010, 8, 173-186.	1.0	18
54	The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity. Life Sciences, 2010, 87, 126-132.	4.3	18

#	Article	IF	CITATIONS
55	Spectrophotometric method for the determination of renal ouabain-sensitive H+,K+-ATPase activity Acta Biochimica Polonica, 2002, 49, 515-527.	0.5	18
56	Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy. Current Pharmaceutical Design, 2014, 20, 616-624.	1.9	17
57	Stimulatory Effect of Leptin on Nitric Oxide Production Is Impaired in Dietaryâ€Induced Obesity. Obesity, 2003, 11, 1571-1580.	4.0	16
58	Up-regulation of renal Na+, K+-ATPase: the possible novel mechanism of leptin-induced hypertension. Polish Journal of Pharmacology, 2004, 56, 213-22.	0.3	16
59	EGF Receptor as a Drug Target in Arterial Hypertension. Mini-Reviews in Medicinal Chemistry, 2009, 9, 526-538.	2.4	15
60	Hydrogen-sulfide-mediated vasodilatory effect of nucleoside 5′-monophosphorothioates in perivascular adipose tissue. Canadian Journal of Physiology and Pharmacology, 2015, 93, 585-595.	1.4	15
61	Antioxidant treatment normalizes renal Na+,K+-ATPase activity in leptin-treated rats. Pharmacological Reports, 2005, 57, 219-28.	3.3	15
62	A novel miRNA-4484 is up-regulated on microarray and associated with increased MMP-21 expression in serum of systemic sclerosis patients. Scientific Reports, 2019, 9, 14264.	3.3	14
63	Adipoparacrinology: an Emerging Field in Biomedical Research. Balkan Medical Journal, 2012, 29, 2-9.	0.8	13
64	TIME-DEPENDENT TRANSITION FROM H2O2?EXTRACELLULAR SIGNAL-REGULATED KINASE- TO O2??NITRIC OXIDE-DEPENDENT MECHANISMS IN THE STIMULATORY EFFECT OF LEPTIN ON RENAL Na+/K+-ATPase IN THE RAT. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1216-1224.	1.9	12
65	Role of PI3K and PKB/Akt in acute natriuretic and NO-mimetic effects of leptin. Regulatory Peptides, 2007, 140, 168-177.	1.9	12
66	Differential effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. Polish Journal of Pharmacology, 2002, 54, 661-71.	0.3	12
67	Time-dependent effect of leptin on renal Na+,K+-ATPase activity Acta Biochimica Polonica, 2005, 52, 803-810.	0.5	10
68	Phosphodiesterase 5 Inhibitor Ameliorates Renal Resistance to Atrial Natriuretic Peptide Associated with Obesity and Hyperleptinemia. Archives of Medical Research, 2006, 37, 307-315.	3.3	9
69	Central vs. peripheral leptin excess in the pathogenesis of obesity-associated hypertension. Journal of Hypertension, 2008, 26, 827-828.	0.5	9
70	Serum paraoxonase-1 activity of dairy Holstein-Fresian cows in different lactation stages – preliminary study. Polish Journal of Veterinary Sciences, 2014, 17, 143-147.	0.2	9
71	The paraoxonase 1 (PON1), platelet-activating factor acetylohydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats. European Journal of Pharmacology, 2016, 789, 187-194.	3.5	9
72	Serum paraoxonase 1 activity and protein N-homocysteinylation in primary human endometrial cancer. Tumor Biology, 2018, 40, 101042831879786.	1.8	9

#	Article	IF	CITATIONS
73	Effect of hyperleptinemia on endothelial nitric oxide production. Atherosclerosis, 2005, 178, 403-404.	0.8	8
74	Nucleoside monophosphorothioates as the new hydrogen sulfide precursors with unique properties. Pharmacological Research, 2014, 81, 34-43.	7.1	8
75	Processes of plasma protein <i>N</i> -homocysteinylation in multiple sclerosis. International Journal of Neuroscience, 2017, 127, 709-715.	1.6	8
76	Paraoxonase 1 Phenotype and Protein N-Homocysteinylation in Patients with Rheumatoid Arthritis: Implications for Cardiovascular Disease. Antioxidants, 2020, 9, 899.	5.1	8
77	Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Polish Journal of Pharmacology, 2002, 54, 143-50.	0.3	8
78	An Integrated View: Neuroadipocrinology of Diabesity. Serbian Journal of Experimental and Clinical Research, 2014, 15, 61-69.	0.1	7
79	The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats. European Journal of Pharmacology, 2019, 850, 180-189.	3.5	6
80	Role of Hydrogen Sulfide and Polysulfides in the Regulation of Lipolysis in the Adipose Tissue: Possible Implications for the Pathogenesis of Metabolic Syndrome. International Journal of Molecular Sciences, 2022, 23, 1346.	4.1	6
81	Spectrophotometric method for the determination of renal ouabain-sensitive H+,K+-ATPase activity. Acta Biochimica Polonica, 2002, 49, 515-27.	0.5	6
82	Effect of Exogenous Hydrogen Sulfide and Polysulfide Donors on Insulin Sensitivity of the Adipose Tissue. Biomolecules, 2022, 12, 646.	4.0	6
83	Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy. Acta Neurologica Scandinavica, 2013, 127, e33-e36.	2.1	5
84	Epicardial adipose tissue: The new target for statin therapy. International Journal of Cardiology, 2019, 274, 353-354.	1.7	5
85	Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-7.	4.0	5
86	Statins and ALS: the possible role of impaired LXR signaling. Medical Science Monitor, 2010, 16, RA73-78.	1.1	5
87	Hydrogen sulfide (H2S): the new member of gasotransmitter family. Biomedical Reviews, 2014, 18, 75.	0.6	4
88	Adipobiology of stem cell-based therapy: secretome insight. Biomedical Reviews, 2014, 21, 57.	0.6	4
89	Inhibition of cell proliferation: a new role of liver X receptors. Clinical Lipidology, 2011, 6, 137-141.	0.4	3
90	Reverse epidemiology in ischemic stroke: high cholesterol as a predictor of improved survival in stroke patients. Clinical Lipidology, 2014, 9, 135-139.	0.4	3

#	Article	IF	CITATIONS
91	Modulation of paraoxonase 1 (PON1) activity and protein N-homocysteinylation by bisphosphonates in rats. Chemico-Biological Interactions, 2016, 259, 401-406.	4.0	3
92	Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats. Chemico-Biological Interactions, 2016, 259, 407-412.	4.0	3
93	Role of progranulin in the regulation of vascular tone: (patho)physiological implications. Acta Physiologica, 2017, 219, 706-708.	3.8	3
94	Short-term follow-up BNP level and risk stratification after myocardial infarction. International Journal of Cardiology, 2019, 291, 173-174.	1.7	3
95	Salt Intake, Aldosterone Secretion, and Obesity: Role in the Pathogenesis of Resistant Hypertension. American Journal of Hypertension, 2021, 34, 588-590.	2.0	3
96	Time-dependent effect of leptin on renal Na+,K+-ATPase activity. Acta Biochimica Polonica, 2005, 52, 803-9.	0.5	3
97	Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions. Current Pharmaceutical Design, 2014, 20, 601-602.	1.9	2
98	Gamma-MSH/MC3R natriuretic signaling system: The possible explanation for contrasting blood pressure effects of agouti mutation and melanocortin receptor knockout. Bioscience Hypotheses, 2008, 1, 243-247.	0.2	1
99	Adipose tussue and homocysteine metabolism. Biomedical Reviews, 2014, 20, 7.	0.6	1
100	Effect of Leptin on Vascular Nitric Oxide and Endothelial Function. Current Hypertension Reviews, 2010, 6, 1-7.	0.9	0
101	Leptin Signaling in Blood Platelets as a Target for Therapeutic Intervention. Current Signal Transduction Therapy, 2011, 6, 20-28.	0.5	0
102	Corrigendum to "Nucleoside monophosphorothioates as the new hydrogen sulfide precursors with unique properties―[Pharmacol. Res. 81 (2014) 34–43]. Pharmacological Research, 2014, 87, 166.	7.1	0
103	Role of epidermal growth factor receptor in the pathogenesis and treatment of arterial hypertension. Biomedical Reviews, 2014, 18, 1.	0.6	0
104	Adipoparacrinology of Atherosclerosis: Evidence Updated. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2012, 12, 2-7.	0.5	0